Observational studyCardiovascular diabetology2024
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI).
Observational study in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Therapeutic impact of SGLT2 inhibitors following transcatheter aortic valve implantation: a grade-assessed systematic review and meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- Association of Sodium-Glucose Cotransporter 2 Inhibitor Use With Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation: A Systematic Review and GRADE-Assessed Meta-Analysis.Cardiovascular therapeutics · 2026Pooled it
- Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials.European heart journal. Cardiovascular pharmacotherapy · 2025Pooled it
- Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography-a subanalysis of the EMPAG-HF trial.European heart journal. Cardiovascular pharmacotherapy · 2025Trial
- Aspirin Versus Clopidogrel as Single Antiplatelet Therapy After TAVI: A Propensity Score-Matched, Retrospective Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Sodium-Glucose Cotransporter-2 Inhibitors in Valvular Heart Disease: From Mechanistic Insights to Clinical Application.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Review
- Sodium-Glucose Cotransporter 2 Inhibitors in Valvular Heart Disease: Cardiovascular Benefit, Valve-Specific Effects, and Evidence Gaps-A Structured Narrative Review.Journal of clinical medicine · 2026Review
- SGLT2 inhibitors after transcatheter aortic valve implantation: a systematic review and exploratory meta-analysis.International journal of cardiology. Heart & vasculature · 2026Article
- Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis.JACC. Basic to translational science · 2026Review
- SGLT-2 Inhibitors and Outcomes After Transcatheter Aortic Valve Implantation: A Systematic Review and Meta-Analysis.JACC. Advances · 2026Article
- Characteristics, clinical outcomes and molecular mechanisms associated with severe diastolic dysfunction in aortic stenosis.Journal of molecular and cellular cardiology plus · 2026Article
- Impact of preprocedural atrial fibrillation and body mass index on clinical outcomes after transcatheter aortic valve implantation.Heart and vessels · 2026Article
- Review
- Shared pathophysiological mechanisms between diabetes and calcific aortic valve disease: an immunometabolic perspective.Cardiovascular diabetology · 2026Review
- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Transcatheter Aortic Valve Replacement: A Real-World Propensity-Matched Analysis.Structural heart : the journal of the Heart Team · 2026Article
- Impact of Perivascular Adipose Tissue Attenuation Around the Aortic Valve on Clinical Outcomes After Transcatheter Aortic Valve Replacement.Journal of the American Heart Association · 2026Article
- SGLT2 Inhibitor Therapy and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with Low Ejection Fraction.Medicina (Kaunas, Lithuania) · 2026Article
- Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Review
- Interplay between medical and interventional therapies in valvular heart disease and heart failure: an expert opinion paper.ESC heart failure · 2026Review
- A novel composite inflammatory-metabolic index for long-term prognosis after TAVR: the modifying role of left ventricular ejection fraction.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
38 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA substantial number of patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI) experience adverse events after TAVI, with health care expenditure. We aimed to investigate cardiac remodeling and long-term outcomes in diabetic patients with severe AS, left ventricular ejection fraction (LVEF) < 50%, and extra-valvular cardiac damage (EVCD) undergoing TAVI treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus other glucose-lowering strategies (no-SGLT2i users).
methodsMulticenter international registry of consecutive diabetic patients with severe AS, LVEF < 50%, and EVCD undergoing TAVI. Based on glucose-lowering therapy at hospital discharge, patients were stratified in SGLT2i versus no-SGLT2i users. The primary endpoint was a composite of all-cause death and heart failure (HF)-hospitalization (major adverse cardiovascular events, MACE) at 2-year follow-up. Secondary outcomes included all-cause death, cardiovascular death, and HF hospitalization.
resultsThe study population included 311 patients, among which 24% were SGLT2i users. Within 1-year after TAVI, SGLT2i users experienced a higher rate of LV recovery (p = 0.032), especially those with baseline LVEF ≤ 30% (p = 0.026), despite the lower baseline LVEF. Patients not treated with SGLT2i were more likely to progress to a worse EVCD stage over time (p = 0.018). At 2-year follow-up, SGLT2i use was associated with a lower rate of MACE, all-cause death, and HF hospitalization (p < 0.01 for all). After adjusting for confounding factors, the use of SGLT2i emerged as an independent predictor of reduced MACE (HR = 0.45; 95% CI 0.17-0.75; p = 0.007), all-cause death (HR = 0.51; 95% CI 0.25-0.98; p = 0.042) and HF-hospitalization (HR = 0.40; 95% CI 0.27-0.62; p = 0.004).
conclusionsIn diabetic patients with severe AS, LVEF < 50%, and EVCD undergoing TAVI, the use of SGLT2i was associated with a more favorable cardiac remodeling and a reduced risk of MACE at 2-year follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.